Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Noemí Puig

Noemí Puig

MD, PhD
University Hospital Salamanca
Evidence supporting MRD-guided treatment breaks in MM 2:37
Evidence supporting MRD-guided treatment breaks in MM
Noemí Puig • 29 Sep 2023
Challenges associated with developing a standardized technique for MRD detection in myeloma 1:02
Challenges associated with developing a standardized technique for MRD detection in myeloma
Noemí Puig • 29 Sep 2023
Using mass spectrometry & NGF to analyze MRD negativity & long-term disease control in NDMM 1:20
Using mass spectrometry & NGF to analyze MRD negativity & long-term disease control in NDMM
Noemí Puig • 29 Sep 2023
The diagnostic and prognostic value of mass spectrometry in multiple myeloma 4:02
The diagnostic and prognostic value of mass spectrometry in multiple myeloma
Noemí Puig • 13 May 2023
The role of PET-CT in the diagnosis and prognosis of multiple myeloma 2:09
The role of PET-CT in the diagnosis and prognosis of multiple myeloma
Noemí Puig • 11 Dec 2022
INSIGHT-MM study update: treatment patterns in first and second-line multiple myeloma 1:26
INSIGHT-MM study update: treatment patterns in first and second-line multiple myeloma
Noemí Puig • 11 Dec 2022
GEM2014MAIN: assessing MRD with NGF in bone marrow and MS in peripheral blood in multiple myeloma 1:24
GEM2014MAIN: assessing MRD with NGF in bone marrow and MS in peripheral blood in multiple myeloma
Noemí Puig • 11 Dec 2022
Advantages & uses of mass spectrometry in the diagnosis and monitoring of multiple myeloma 2:40
Advantages & uses of mass spectrometry in the diagnosis and monitoring of multiple myeloma
Noemí Puig • 26 Aug 2022
Current & emerging biomarkers in multiple myeloma 3:00
Current & emerging biomarkers in multiple myeloma
Noemí Puig • 26 Aug 2022
Applications of the heavy/light chain assay in multiple myeloma 2:05
Applications of the heavy/light chain assay in multiple myeloma
Noemí Puig • 26 Aug 2022
GEM-CLARIDEX: improved CR rate but no difference in PFS at 19 months of follow-up 4:56
GEM-CLARIDEX: improved CR rate but no difference in PFS at 19 months of follow-up
Noemí Puig • 24 Jun 2021
INSIGHT-MM: real-world analysis of DOT with Rd-based regimens in R/R myeloma 4:12
INSIGHT-MM: real-world analysis of DOT with Rd-based regimens in R/R myeloma
Noemí Puig • 8 Jun 2021
GEM2012MENOS65: treatment response assessment by mass spectrometry 3:59
GEM2012MENOS65: treatment response assessment by mass spectrometry
Noemí Puig • 8 Jun 2021
qIP-MS in high-risk myeloma patients in the GEM-CESAR trial 4:19
qIP-MS in high-risk myeloma patients in the GEM-CESAR trial
Noemí Puig • 23 Jun 2020
Updates from the GEM-CLARIDEX study in myeloma 3:34
Updates from the GEM-CLARIDEX study in myeloma
Noemí Puig • 23 Jun 2020
INSIGHT-MM: real-world patterns of patient characteristics 4:12
INSIGHT-MM: real-world patterns of patient characteristics
Noemí Puig • 23 Jun 2020
The content of VJHemOnc is intended for healthcare professionals